A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation

Trial Profile

A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs Elosulfase alfa (Primary)
  • Indications Mucopolysaccharidosis IV
  • Focus Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 29 Feb 2016 Data from this trial will be presented at the 12th Annual WORLDSymposium, according to a BioMarin media release.
    • 31 Jan 2015 New source identified and integrated (European Clinical Trials Database record: EudraCT2011-005703-33)
    • 07 Dec 2014 Status changed from active, no longer recruiting to discontinued,as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top